Clinical, cosmetic and investigational dermatology · 2025
Topical Glucocorticoid-Induced Cushing's Syndrome in a Patient with Erythrodermic Psoriasis: A Case Report.
Клинический случайСтатьяНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Peng Xing, Quan Gen, She Xiao-Guang, Wu Jing-Jing, Ge Qin
Аннотация
BACKGROUND: Topical glucocorticoids are widely used in psoriasis treatment but may lead to systemic adverse effects, particularly with prolonged use. While pediatric cases are well-documented, adult-onset iatrogenic Cushing's syndrome from topical corticosteroids remains under-recognized.
CASE PRESENTATION: A 31-year-old woman with a 10-year history of psoriasis vulgaris self-administered high-potency clobetasol propionate ointment (monthly cumulative dose escalated from 30 g to 100 g over 22 months) under no physician supervision. She presented with erythrodermic psoriasis and Cushingoid features (moon facies, violaceous striae, pitting oedema). Laboratory tests confirmed suppressed cortisol (<1.5 nmol/L) and ACTH (2.86 pg/mL). Management included gradual withdrawal of topical steroids, initiation of oral methylprednisolone (8 mg daily) for HPA axis support, and transition to low-potency desonide. Four-month follow-up showed normalization of cortisol levels (167.1 nmol/L at 8:00 AM).
CONCLUSION: This case highlights the systemic risks of unsupervised, escalating use of high-potency topical corticosteroids in adults with impaired skin barrier. It underscores the need for adherence to dosing guidelines, patient education, and routine endocrine monitoring.
CASE PRESENTATION: A 31-year-old woman with a 10-year history of psoriasis vulgaris self-administered high-potency clobetasol propionate ointment (monthly cumulative dose escalated from 30 g to 100 g over 22 months) under no physician supervision. She presented with erythrodermic psoriasis and Cushingoid features (moon facies, violaceous striae, pitting oedema). Laboratory tests confirmed suppressed cortisol (<1.5 nmol/L) and ACTH (2.86 pg/mL). Management included gradual withdrawal of topical steroids, initiation of oral methylprednisolone (8 mg daily) for HPA axis support, and transition to low-potency desonide. Four-month follow-up showed normalization of cortisol levels (167.1 nmol/L at 8:00 AM).
CONCLUSION: This case highlights the systemic risks of unsupervised, escalating use of high-potency topical corticosteroids in adults with impaired skin barrier. It underscores the need for adherence to dosing guidelines, patient education, and routine endocrine monitoring.